vs
Side-by-side financial comparison of Bandwidth Inc. (BAND) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Bandwidth Inc. is the larger business by last-quarter revenue ($208.8M vs $168.4M, roughly 1.2× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 20.1%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 9.7%).
Bandwidth Inc. is a communications platform as a service company. It sells software application programming interfaces for voice, text messaging and emergency services, using its own global IP voice network.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
BAND vs ESPR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $208.8M | $168.4M |
| Net Profit | $4.0M | — |
| Gross Margin | 37.3% | — |
| Operating Margin | 60.5% | 50.6% |
| Net Margin | 1.9% | — |
| Revenue YoY | 20.1% | 143.7% |
| Net Profit YoY | 200.0% | — |
| EPS (diluted) | $-0.08 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $208.8M | — | ||
| Q4 25 | $207.7M | $168.4M | ||
| Q3 25 | $191.9M | $87.3M | ||
| Q2 25 | $180.0M | $82.4M | ||
| Q1 25 | $174.2M | $65.0M | ||
| Q4 24 | $210.0M | $69.1M | ||
| Q3 24 | $193.9M | $51.6M | ||
| Q2 24 | $173.6M | $73.8M |
| Q1 26 | $4.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $-1.2M | $-31.3M | ||
| Q2 25 | $-4.9M | $-12.7M | ||
| Q1 25 | $-3.7M | $-40.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | $413.0K | $-29.5M | ||
| Q2 24 | $4.1M | $-61.9M |
| Q1 26 | 37.3% | — | ||
| Q4 25 | 37.6% | — | ||
| Q3 25 | 38.5% | — | ||
| Q2 25 | 39.8% | — | ||
| Q1 25 | 41.0% | — | ||
| Q4 24 | 36.4% | — | ||
| Q3 24 | 37.7% | — | ||
| Q2 24 | 37.3% | — |
| Q1 26 | 60.5% | — | ||
| Q4 25 | -1.9% | 50.6% | ||
| Q3 25 | -1.0% | -11.4% | ||
| Q2 25 | -2.1% | 8.6% | ||
| Q1 25 | -2.7% | -34.0% | ||
| Q4 24 | -1.3% | -6.4% | ||
| Q3 24 | -0.5% | -31.0% | ||
| Q2 24 | -3.5% | 3.5% |
| Q1 26 | 1.9% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | -0.6% | -35.9% | ||
| Q2 25 | -2.7% | -15.4% | ||
| Q1 25 | -2.1% | -62.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.2% | -57.2% | ||
| Q2 24 | 2.3% | -83.9% |
| Q1 26 | $-0.08 | — | ||
| Q4 25 | $-0.10 | $0.32 | ||
| Q3 25 | $-0.04 | $-0.16 | ||
| Q2 25 | $-0.16 | $-0.06 | ||
| Q1 25 | $-0.13 | $-0.21 | ||
| Q4 24 | $0.27 | $-0.14 | ||
| Q3 24 | $0.01 | $-0.15 | ||
| Q2 24 | $-0.17 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $47.3M | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $405.7M | $-302.0M |
| Total Assets | $984.2M | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $47.3M | — | ||
| Q4 25 | $111.3M | $167.9M | ||
| Q3 25 | $80.4M | $92.4M | ||
| Q2 25 | $68.1M | $86.1M | ||
| Q1 25 | $41.7M | $114.6M | ||
| Q4 24 | $83.8M | $144.8M | ||
| Q3 24 | $79.9M | $144.7M | ||
| Q2 24 | $76.4M | $189.3M |
| Q1 26 | $405.7M | — | ||
| Q4 25 | $400.0M | $-302.0M | ||
| Q3 25 | $392.7M | $-451.4M | ||
| Q2 25 | $384.5M | $-433.5M | ||
| Q1 25 | $345.4M | $-426.2M | ||
| Q4 24 | $312.5M | $-388.7M | ||
| Q3 24 | $336.6M | $-370.2M | ||
| Q2 24 | $307.4M | $-344.2M |
| Q1 26 | $984.2M | — | ||
| Q4 25 | $1.1B | $465.9M | ||
| Q3 25 | $1.0B | $364.0M | ||
| Q2 25 | $1.0B | $347.1M | ||
| Q1 25 | $964.4M | $324.0M | ||
| Q4 24 | $989.2M | $343.8M | ||
| Q3 24 | $1.0B | $314.1M | ||
| Q2 24 | $1.0B | $352.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $45.2M |
| Free Cash FlowOCF − Capex | $-1.0M | — |
| FCF MarginFCF / Revenue | -0.5% | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $38.6M | $45.2M | ||
| Q3 25 | $22.2M | $-4.3M | ||
| Q2 25 | $31.7M | $-31.4M | ||
| Q1 25 | $-3.1M | $-22.6M | ||
| Q4 24 | $36.5M | $-35.0M | ||
| Q3 24 | $20.5M | $-35.3M | ||
| Q2 24 | $24.4M | $-7.2M |
| Q1 26 | $-1.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-35.5M | ||
| Q2 24 | — | $-7.3M |
| Q1 26 | -0.5% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -68.7% | ||
| Q2 24 | — | -9.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 49.55× | — | ||
| Q2 24 | 6.03× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BAND
Segment breakdown not available.
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
